Anticipated $0.09 EPS for Enanta Pharmaceuticals, Inc. (ENTA) as of May, 14

April 17, 2018 - By Nellie Rakes

During 2017 Q4 the big money sentiment decreased to 1.58. That’s change of 0.02, from 2017Q3’s 1.6. 12 investors sold all, 36 reduced holdings as Enanta Pharmaceuticals, Inc. ratio turned negative. 47 rose stakes while 29 funds acquired stakes. Funds hold 13.64 million shares thus 12.66% more from 2017Q3’s 12.10 million shares.
Cubist Systematic Strategies Limited Liability Company owns 4,607 shs for 0.01% of their capital. Matarin Cap Lc invested in 286,957 shs. New York State Teachers Retirement System stated it has 38,490 shs. Ubs Asset Mngmt Americas reported 4,100 shs. Prelude Capital Mngmt Lc holds 146 shs or 0% of its capital. Proshare Advsrs Ltd reported 0.01% of its capital in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Millennium Management Ltd Liability Corporation accumulated 220,845 shs. Great West Life Assurance Can owns 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 19,835 shs. Eqis Mngmt has 0.09% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Arizona State Retirement Sys has invested 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Renaissance Limited Liability Corp holds 0.05% or 771,600 shs in its capital. Guggenheim Ltd owns 53,176 shs or 0.01% of their US capital. Dekabank Deutsche Girozentrale has 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Acadian Asset Mgmt Lc accumulated 25,489 shs or 0.01% of the stock. State Board Of Administration Of Florida Retirement, Florida-based fund reported 16,193 shs.

Enanta Pharmaceuticals, Inc. had 1 insider sale and 0 insider purchases since March 19, 2018. This’s net activity of $778,331.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)’s earnings report is expected On May, 14., according to Faxor. EPS of $0.09 is 132.14 % up from 2017’s $-0.28 EPS. The profit will be $1.72 million for ENTA if $0.09 EPS becomes true. Wall Street now predicts -88.46 % negative EPS growth despite Enanta Pharmaceuticals, Inc. last quarter’s EPS of $0.78. Its shares touched $87.31 on during the last trading session after 1.58% change.Currently Enanta Pharmaceuticals, Inc. is uptrending after 160.80% change in last April 17, 2017. ENTA has 13,093 shares volume. ENTA outperformed by 149.25% the S&P500.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Ratings Coverage

In total 4 analysts cover Enanta Pharmaceuticals (NASDAQ:ENTA). “Buy” rating has 0, “Sell” are 0, while 4 are “Hold”. 0 are bullish. 9 are the (NASDAQ:ENTA)’s analyst reports since October 20, 2017 according to StockzIntelligence Inc. On Monday, November 20 Robert W. Baird maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) with “Hold” rating. On Wednesday, April 4 the stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has “Hold” rating given by RBC Capital Markets. On Friday, October 20 the rating was maintained by RBC Capital Markets with “Buy”. On Friday, October 20 Robert W. Baird maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) rating. Robert W. Baird has “Hold” rating and $36.0 target. On Thursday, February 8 J.P. Morgan downgraded the shares of ENTA in report to “Hold” rating. In Monday, November 20 report RBC Capital Markets maintained it with “Buy” rating and $58.0 target. The stock rating was downgraded by RBC Capital Markets to “Sector Perform” on Tuesday, January 2. The stock rating was downgraded by JP Morgan to “Neutral” on Thursday, February 8. In Thursday, February 8 report Robert W. Baird maintained the stock with “Hold” rating.

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases.The firm is valued at $1.67 billion. The company??s research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.The P/E ratio is 49.86. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.